News

Corbus Pharmaceuticals Unveils Positive Results for CRB-913

Corbus Pharmaceuticals Unveils Positive Results for CRB-913

Corbus Pharmaceuticals Achieves Milestone with CRB-913

In the realm of innovative treatments for obesity, Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) has marked an important milestone with its oral CB1 inverse agonist, CRB-913. Recently, the clinical-stage company announced that it has successfully completed the Phase 1a study, showcasing a favorable safety profile along with encouraging preliminary evidence suggesting its ability to facilitate weight loss. This promising data paves the way for further studies aimed at combating obesity, a condition that affects millions globally, and represents a growing concern in public health.

Results from Phase 1a Study

The Phase 1a study incorporated both single ascending dose (SAD) and multiple ascending dose (MAD) evaluations to assess CRB-913's safety, tolerability, and pharmacokinetics (PK). What stood out from this study was the overwhelming evidence that CRB-913 was both safe and well-tolerated across all doses examined. With stringent monitoring through daily neuropsychiatric assessments, it was reassuring to observe negative results on the Columbia-Suicide Severity Rating Scale (CSSRS), the Patient Health Questionnaire-9 (PHQ-9), and the General Anxiety Disorder-7 (GAD-7) questionnaires, ensuring participant safety throughout. Encouragingly, no serious treatment-emergent adverse events were reported.

Weight Loss Findings

Participants in the dedicated cohort, characterized by chronic obesity, exhibited a significant placebo-adjusted mean weight loss of 2.9% by Day 14. This exceeded expectations, especially given that all treated individuals experienced weight loss without the side effects typically associated with weight-loss medications. The study enrolled 12 participants suffering from obesity and 64 healthy volunteers, exploring the dosage and effectiveness of CRB-913 under controlled conditions.

Upcoming Phase 1b Study

Building on the momentum of these initial findings, Corbus Pharmaceuticals is eager to launch its Phase 1b clinical trial known as CANYON-1, aimed at a larger population with obesity. This upcoming 12-week study will involve 240 participants who are non-diabetic and include various cohorts for dose-ranging. The goal is to solidify the efficacy of CRB-913 as a therapeutic option for chronic obesity management. Expected to begin shortly, this next phase of research is viewed as crucial in establishing CRB-913’s therapeutic profile, with researchers excited about the potential outcomes.

Expert Insights and Future Directions

Dr. Yuval Cohen, Chief Executive Officer of Corbus, expressed optimism regarding the transition of CRB-913 from pre-clinical testing to clinical application. He highlighted its class-leading safety and tolerability profile as critical attributes that distinguish CRB-913 from prior substance class candidates that faced challenges due to adverse events. He also noted that participants reported a reduction in food cravings and related thoughts, suggesting a behavioral impact which could underpin long-term treatment for obesity.

In Summary: A Promising Future

With a solid start in clinical trials, Corbus Pharmaceuticals is positioned to drive forward its mission of addressing obesity through innovative methodologies. The promising findings from the Phase 1a study demonstrate a significant advancement, contributing to a collaborative effort in the fight against obesity and its related health challenges. The upcoming Phase 1b study will provide a crucial opportunity to confirm the initial findings and pave the way for future treatment options that target this prevalent condition.

Frequently Asked Questions

What is CRB-913?

CRB-913 is an oral small molecule inverse agonist designed for the treatment of obesity, targeting the CB1 receptor with a favorable safety profile.

What were the key findings from the Phase 1a study?

The Phase 1a study demonstrated that CRB-913 was safe and well-tolerated, with a placebo-adjusted mean weight loss of 2.9% observed in participants.

When does the Phase 1b CANYON-1 study start?

The Phase 1b study is expected to begin shortly, aiming to expand on the findings from the Phase 1a study.

How many participants are involved in the Phase 1b trial?

The upcoming Phase 1b trial will involve 240 obese, non-diabetic participants across multiple clinical sites.

What differentiates CRB-913 from older weight-loss drugs?

CRB-913 is distinguished by its peripherally restricted mechanism, which aims to minimize neuropsychiatric side effects noted in previous weight-loss medications.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 100

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 67

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Salvation Army’s Angel Tree: 2026 Holiday Cheer Drive

Updated Category News Views 162

Kickstarting Holiday Generosity: The Angel Tree Program Man, there's something heartwarming about a Christmas that shines bright for everyone. The Salvation Army's Angel Tree program is back for another season, rolling up with a mission to spark joy across the country. For over 45 years now, this initiative's been the answer to many Christmas wish lists, especially for...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 207

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 69

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 120

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading
NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 65

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 94

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 173

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 90

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover the New Beach Bungalows at Margaritaville Resort

Updated Category News Views 98

Unveiling the Beach Bungalows at Margaritaville Resort Camp Margaritaville Resort Crystal Beach is thrilled to unveil its brand-new residential offering, the Beach Bungalows. This exciting development invites potential homeowners to experience life along the enchanting shores of Crystal Beach. Experience Coastal Living Like Never Before For those seeking a tranquil...

Continue Reading
Carrier Global Corporation Declares New Quarterly Dividend

Updated Category News Views 199

Carrier Global Corporation Announces Quarterly Cash Dividend Carrier Global Corporation (NYSE: CARR), a leading entity in intelligent climate and energy solutions, is excited to inform its stakeholders about the declaration of a quarterly cash dividend. This dividend amounts to $0.225 for each share of the common stock held by shareholders. Dividend Payment and Record...

Continue Reading
Investors Alert: Class Action Filed Against Synopsys, Inc.

Updated Category News Views 127

Understanding the Class Action Lawsuit Against Synopsys, Inc. Recently, a class action lawsuit has been initiated against Synopsys, Inc. (NASDAQ: SNPS), centered around claims of securities fraud. This move, announced by Bernstein Liebhard LLP, has raised significant attention among shareholders who purchased or acquired securities of the Company. Who Should Be Concerned?...

Continue Reading
Modern Pediatrics Introduces Affordable Care with Home Visits

Updated Category News Views 319

Modern Pediatrics Launches Affordable Pediatric Care in Dallas Modern Pediatrics, a concierge pediatrics group based in Austin, is excited to bring their innovative services to the Dallas area. They are now offering in-home pediatric visits and 24/7 virtual care, a service that is truly a game-changer for families seeking accessible healthcare. Historically, home-based...

Continue Reading
Texas Pacific Land Corp Reports Insider Stock Purchases

Updated Category News Views 95

Executives at Texas Pacific Land Corp Make Noteworthy Stock Purchases Recently, executives at Texas Pacific Land Corp (NYSE: TPL), a key player in the oil royalty trading sector, made significant stock purchases. These transactions, revealed through recent SEC filings, were conducted under a prearranged trading plan, which allows insiders to buy shares without raising...

Continue Reading